WallStreetZenWallStreetZen

NASDAQ: PSTV
Plus Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PSTV

Based on 3 analysts offering 12 month price targets for Plus Therapeutics Inc

Min Forecast
$3.00+525%
Avg Forecast
$10.83+2,156.88%
Max Forecast
$20.50+4,170.83%

Should I buy or sell PSTV stock?

Based on 3 analysts offering ratings for Plus Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PSTV stock forecasts and price targets.

PSTV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-27Find Out Why
lockedlocked$00.00+00.00%2025-06-25
lockedlocked$00.00+00.00%2025-06-05

1 of 1

Forecast return on equity

Is PSTV forecast to generate an efficient return?

Company
N/A
Industry
165.49%
Market
90.49%

Forecast return on assets

Is PSTV forecast to generate an efficient return on assets?

Company
-8.14%
Industry
47.74%
PSTV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PSTV earnings per share forecast

What is PSTV's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.08
Avg 2 year Forecast
-$0.45
Avg 3 year Forecast
-$0.34

PSTV revenue forecast

What is PSTV's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$7.2M+37.44%
Avg 2 year Forecast
$8.1M+54.73%
Avg 3 year Forecast
$17.3M+231.54%
PSTV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PSTV revenue growth forecast

How is PSTV forecast to perform vs Biotechnology companies and vs the US market?

Company
41.94%
Industry
67.64%
Market
10.7%
PSTV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PSTV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PSTV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PSTV$0.48$10.83+2,156.88%Buy
ABP$0.26$4.00+1,450.39%Strong Buy
ALLR$1.04$9.00+765.38%Buy
EDSA$2.25$13.00+477.78%Buy
MRKR$1.40$10.25+632.14%Strong Buy
View Top Biotech Stocks

Plus Therapeutics Stock Forecast FAQ

Is Plus Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PSTV) stock is to Buy PSTV stock.

Out of 3 analysts, 0 (0%) are recommending PSTV as a Strong Buy, 2 (66.67%) are recommending PSTV as a Buy, 1 (33.33%) are recommending PSTV as a Hold, 0 (0%) are recommending PSTV as a Sell, and 0 (0%) are recommending PSTV as a Strong Sell.

If you're new to stock investing, here's how to buy Plus Therapeutics stock.

What is PSTV's earnings growth forecast for 2025-2027?

(NASDAQ: PSTV) Plus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.57%.

Plus Therapeutics's earnings in 2025 is -$27,118,000.On average, 1 Wall Street analyst forecast PSTV's earnings for 2025 to be $2,617,364, with the lowest PSTV earnings forecast at $2,617,364, and the highest PSTV earnings forecast at $2,617,364. On average, 2 Wall Street analysts forecast PSTV's earnings for 2026 to be -$14,559,089, with the lowest PSTV earnings forecast at -$19,957,403, and the highest PSTV earnings forecast at -$9,160,775.

In 2027, PSTV is forecast to generate -$11,123,798 in earnings, with the lowest earnings forecast at -$11,123,798 and the highest earnings forecast at -$11,123,798.

What is PSTV's revenue growth forecast for 2025-2027?

(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 41.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 67.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Plus Therapeutics's revenue in 2025 is $5,206,000.On average, 2 Wall Street analysts forecast PSTV's revenue for 2025 to be $234,090,521, with the lowest PSTV revenue forecast at $130,868,216, and the highest PSTV revenue forecast at $337,312,827. On average, 2 Wall Street analysts forecast PSTV's revenue for 2026 to be $263,535,870, with the lowest PSTV revenue forecast at $130,868,216, and the highest PSTV revenue forecast at $396,203,524.

In 2027, PSTV is forecast to generate $564,696,352 in revenue, with the lowest revenue forecast at $564,696,352 and the highest revenue forecast at $564,696,352.

What is PSTV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PSTV) forecast ROA is -8.14%, which is lower than the forecast US Biotechnology industry average of 47.74%.

What is PSTV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PSTV price target, the average PSTV price target is $10.83, with the highest PSTV stock price forecast at $20.50 and the lowest PSTV stock price forecast at $3.00.

On average, Wall Street analysts predict that Plus Therapeutics's share price could reach $10.83 by Jun 27, 2026. The average Plus Therapeutics stock price prediction forecasts a potential upside of 2,156.88% from the current PSTV share price of $0.48.

What is PSTV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PSTV) Plus Therapeutics's current Earnings Per Share (EPS) is -$2.50. On average, analysts forecast that PSTV's EPS will be $0.08 for 2025, with the lowest EPS forecast at $0.08, and the highest EPS forecast at $0.08. On average, analysts forecast that PSTV's EPS will be -$0.45 for 2026, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.28. In 2027, PSTV's EPS is forecast to hit -$0.34 (min: -$0.34, max: -$0.34).

What is PSTV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PSTV) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.